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Invariably mesothelioma is diagnosed late in the development of the disease when treatment is
no longer effective. Therefore, a key to reducing the mortality rate of this neoplasm is knowledge
of the general sequence of genetic events between initiation of mesothelial cells and the
emergence of the metastatic tumor cells. Unfortunately, relatively little is known about the early
changes in the genesis of this disease. Of the known changes, the most frequent are in the
tumor-suppressor genes p161NK4 and NF2and possibly the SV40 virus large T-antigen oncogene.
The molecular nature of the changes in these genes as well as other alterations are addressed in
this overview. Environ Health Perspect 105(Suppl 5):1061-1067 (1997)
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Delineating the genetic changes that
produce a cell with uncontrolled and often
unlimited growth potential is important to
the understanding ofcarcinogenesis mech-
anisms. Knowledge of these molecular
processes also enhances the design ofearly
detection and therapeutic protocols.
Unfortunately, relatively minimal informa-
tion is available on cancers associated with
fiber exposure. This overview summarizes
these observations, with primary emphasis
on the alterations that have been described
in human mesotheliomas.
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Molecular Pathways
ofGrowth Control
Progression ofeukaryotic cells through their
cell cyde is regulatedbythesequential forma-
tion, activation, and inactivation ofa series of
cyclin/cydlin-dependent kinase (CDK) com-
plexes. In addition to positive regulation by
the activation ofcyclin/CDK complexes,
negative regulation ofthe cell cycle occurs
through cyclin-dependent kinase inhibitors
(CKIs) to prevent premature entry into the
next phase ofthe cyde before completion of
necesay macromolecular reactions (1-3).
Cell replication begins at the restriction
point (R Figure 1), where growth and arrest
signals from theextracellular environment are
integrated to determine whether the cell
divides or remains quiescent (1-3). For
example, elevated expression ofplatelet-
derived growth factor (PDGF), which is a
hallmark ofmesothelioma, can elevate the
concentration of c-mycin the nudeus. c-myc
then induces the expression ofcyclin Ds, and
the balance between cycin D/CDK4 and its
CKI is tippedtoward more rapid cell division
(3). Once a growth-positive balance ofthese
factors has developed, the cell is committed
to traverse the cell cyde.
In the first phase (Gi), different species
ofcydin D (DI, D2, D3) are expressed and
form complexes with CDK4 and CDK6
(1,2,4). The activated cyclin/CDK com-
plexes phosphorylate the retinoblastoma
(Rb) gene product and its related proteins
(pI07, p130). When these proteins are
hypophosphorylated, they are complexes
with transcription factors, e.g., E2F; hyper-
phosphorylation ofthe Rb protein releases
these transcription factors (1,2,4-6), which
then stimulate the transcription ofmRNAs
that encode proteins required for the cell to
progress further through the cell cycle
(1,2,4,5). The next complex, cyclin
E/CDK2, further phosphorylates Rb family
proteins, and the cell begins to synthesize
DNA. Once the cell enters S phase, i.e.,
begins to synthesize DNA, a complex
between cyclin A and CDK2 kinase forms.
This complex, whose role is unclear, is
degraded as the cell enters the G2 phase.
Finally, the cyclin B/CDC2 complex phos-
phorylates proteins involved in chromo-
some condensation and the progression of
the cell through mitosis, e.g., HI histone,
nuclear lamins, nudeolin, and intermediate
filaments (1,2).
Two checkpoints in thecell cydeprovide
the cell with opportunities to govern its rate
ofcycling. The first, which is at the G1/S
border, employs proteins denoted as CKIs.
Currently, two structurally defined classes
are known. The first, exemplified by
pl6INK4a and pi5INK4b and induding p19
and p18, primarily regulates CDK4 and
CDK6 (7,8) by binding to the associated
cydins (9). The second family, characterized
by 21cip1, and including p27KIPl and
p57KP2, regulates the activities ofthe CDK2
and CDK4/6 complexes (1,2,4). As will be
discussed later, aberrations in the G1/S
checkpoint function are associated with
mesothelioma. Inhibitor proteins that pre-
vent the activation ofthe cyclin B/CDC2
complex at the G2/M checkpoint also have
been described (1,2), but no correlations
between these proteins and fiber-caused car-
cinogenesis have been reported. However,
because disruption ofmitotic processes is a
salient feature ofcell-fiber interactions
(10-14), examining mesothelioma cells for
aberrations ofthe G2/M checkpoint genes
may identify one or more that are highly
correlatedwithmesothelioma.
Expression ofCKI genes is stimulated
by stress factors. For example, damaged
DNA initiates events that cause the p53
gene product to accumulate within the cell
nucleus (15,16). This protein induces the
transcription of certain genes while
inhibiting others. Two major regulatory
proteins induced by the accumulation of
p53 are the kinase inhibitorp2lCiPl and the
protooncogene mdm2 (15). The ability of
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Figure 1. Relationships of genes involved in mesothelial cell carcinogenesis to the cell cycle.
p53 to arrest cell growth can be explained
in part by its ability to induce the kinase
inhibitor p21CiPl, which inhibits the action
of the G1 phase cyclin-CDK complexes
(1). During the arrest period, the DNA
damage is repaired. p53 also initiates tran-
scription of the protooncogene mdm2,
which then inactivates the p53 protein.
This decrease in p53 activity leads to the
fall in concentration ofp21CiP1 protein, and
the cell resumes its progress through the cell
cycle (17).
The cell cycle is permanently stopped
by programmed cell death, e.g., apoptosis.
Overabundance of the Bax protein pro-
motes apoptosis; on the other hand, excess
Bcl-2 protein can extend cell survival by
preventing apoptosis. Excessive damage to
DNA elevates the concentration ofthep53
gene product, which transactivates expres-
sion ofthe Bax protein (18). This mecha-
nism is responsible for apoptotic death ofa
potentially mutant cell. However, ifp53 is
dysfunctional or is inactivated by binding
with excess mdm2 protein, Baxlevels remain
low and the mutated cell can survive.
Alternatively, inappropriate expression of
various growth factors or growth factor
intermediates can cause overexpression of
Bcl-2, which prevents programmed cell
death (18), in part by inhibiting expression
ofp21ClPl (19). Consequently, mutated
cells continue to replicate.
Tumor-Suppressor Genes
in Mesotheliomas
Tumor-suppressor genes check and regulate
cell division. In general, these genes can
become aberrant bypoint mutation, partial
deletion, inappropriate expression, epige-
netic silencing, gene amplification, gene
rearrangement, complete gene loss, or
combinations of these mechanisms. All
could be involved in the genesis of a
mesothelioma from exposure to asbestos.
However, a hallmark of human (10-14,
20-34) and rodent (35-37) mesotheliomas
is the large number of their nonrandom
cytogenetic alterations. For human tumors,
these include monosomy or partial mono-
somy ofchromosomes 1, 3, 4, 6, 9, 14, 15,
18, 19, and 22, and trisomies and polysomies
ofchromosomes 1, 5, 7, 11, 12, and 20.
This array of nonrandom chromosome
deletions in human mesotheliomas suggests
that many tumor-suppressor genes and
oncogenes are probablyinvolved in the gen-
esis of the disease. The tumor-suppressor
genes located at bands lp21-22, 3p2l,
6ql5-21, and 22q will be identified even-
tually because these cytogenetic regions are
involved in the genesis ofother human can-
cers (21,26,28,30-34,38). However, cur-
rent information confirms the involvement
ofonly the following five tumor suppressor
genes, i.e., pl6NK4, pl5INK4b, p53 NF2
and WT1.
Cytogenetic analyses have shown that
chromosome bands 9pl3 to p22 are deleted
in 50% of mesotheliomas. Two known
tumor suppressors have been mapped to
this region: the CDK4,6 inhibitors
p16INK a and p15INK4b (39). Cheng et al.
(40) showed that 85% of the mesothelial
cell lines they investigated had a homo-
zygous deletion ofp16INK4a. However, only
22% of the primary tumors showed this
deletion. In contrast, Xiao and co-workers
(39) reported that both ofthese genes were
deleted in more than 70% ofprimar1
mesotheliomas. A similar loss ofp16INK a
was recently reported by Kratzke et al. (41).
In addition, these authors showed that
when pI 6INK4a was transfected into
mesothelioma cell lines, their growth rates
were inhibited 5- to 10-fold. In parallel,
Spillare et al. (42) showed a 50% inhibi-
tion of colony-forming efficiency when
p16INK4a was transfected into cultured
mesothelioma cells. Several primary
mesotheliomas exhibit cell heterogeneity
for expression ofp16INK4a and p15INK4b
implying that the loss of these genes was a
late event (41). On the other hand, a pri-
mary consequence of asbestos exposure is
extensive chromosome alterations (11,24).
Thus, it is also possible that these genes
were deleted as adirect result ofafiber inter-
acting with chromatin or spindle proteins
(43). In human lung tumor cells, loss of
pl6INK4a is inversely related to retaining
the Rb tumor-suppressor gene, and vice
versa (41). Mesotheliomas follow this rule
as well; three studies have shown that Rb is
not deleted in these tumors (44-46).
The p53 tumor-suppressor gene, which
resides in band p13 of chromosome 17,
shows the most frequent rate of genetic
alteration in human cancers, especially of
the lung (15). In support ofthis statement,
Cote et al. (47) found that three of four
mesothelioma cell lines exhibited an abnor-
mal p53 gene. Specifically, two had point
mutations, and the third did not transcribe
p53 mRNA. One of the cell lines with a
point mutation, as well as the nontranscrib-
ing line, also showed loss ofheterozygosity
for 17p. However, Metcalfet al. (48) ana-
lyzed 20 mesothelioma cell lines and found
that only 2 had point mutations, and 1
failed to transcribe p53. These latter data are
in accord with the fact that mesotheliomas
with deletions of chromosome 17p have
been reported only occasionally (22,24).
These data on human mesothelioma con-
trast with murine data where frequent
(76%) rearrangement ofthe gene was found
and p53 mRNA expression was frequently
reduced orabsent (49).
p53 overexpression in the nucleus often
reflects abnormal p53 function (15).
Metcalfet al. (48) reported that three ofthe
lines without mutations exhibited strong
staining ofp53 protein, while most ofthe
others showed some positive cells. Further,
Mayall et al. (50), Kafiri et al. (51), and
Segers et al. (52) reported strong immuno-
staining ofp53 protein in tumor sections.
As noted by Metcalfet al. (48), p53 expres-
sion without gene mutation suggests upreg-
ulation ofp53 because ofoverexpression of
c-myc, or perhaps the stabilization of the
protein because of complexing with an
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oncogene. The latter mechanism is sup-
ported by Segers et al. (52); 60% ofthep53
immunopositive but nonmutated tumors
they evaluated also overexpressed thep53-
inactivating oncogene mdm2. However,
Ungar et al. (53) recently reported that
mdm2 was not overexpressed in the 17
mesothelioma cell lines theyanalyzed.
A second p53-inactivating mechanism
could be the expression of the T-antigen
(T-ag) ofthe SV40 virus. In cells that have
been infected, the p53 protein apparently
is overexpressed because it is complexed
with large T-ag. This virus causes mesothe-
liomas when injected into the pleural space
ofhamsters (54). Further, Carbone et al.
(55) recovered fragments of SV40-like
DNA sequences from 60% of the meso-
theliomas they examined by polymerase
chain reaction (PCR). In addition, 79% of
the tumors exhibited SV40 T-ag when
assessed using immunohistochemistry, and
there was a high correlation between T-ag
immunoreactivity and the presence ofSV40
sequences. Subsequently, Cristaudo et al.
(56) found the same SV40-like DNA
sequences in 72% of the mesotheliomas
they investigated. In contrast, Metcalfet al.
(48) found no evidence ofSV40 T-ag in
any ofthe 20 mesothelioma cell lines they
investigated using immunohistochemistry.
Further conflicting information, however, is
in the recent report by Galateau-Salle et al.
(57). These authors showed that SV40-like
sequences are found not only in some
mesotheliomas but also in pleural plaques,
lung tumors, parenchyma distal to the
tumors, and in parenchyma ofindividuals
without cancer.
The NF2 autosomal dominant tumor-
suppressor gene resides on chromosome 22
(58). As noted above, this chromosome
frequently is abnormal in mesotheliomas
(24). Consequently, this gene has been
evaluated in several cell lines. The results
show that frameshift and nonsense muta-
tions, and deletions ofsmall portions ofthe
NF2 gene were often present in cell lines
(58,59). These aberrations also have been
found frequently in primary mesothe-
liomas (59), but they are rare in human
lung carcinomas (59). NF2 codes for a
protein called merlin, which may play a
role in cell surface dynamics and structure
by linking the cytoskeleton to the plasma
membrane (58). Asbestos fibers are known
to be more efficient in deforming the
cytoskeleton in mesothelial cells than in
airway epithelial cells (10). Thus, loss of
stabilizing function supplied by a normal
NF2 gene product may be involved in the
mechanism offiber-caused transformation
ofthe mesothelial cell.
A small percentage of mesotheliomas
exhibit a cytogenic aberration-an intersti-
tial deletion ofbands 1ipl1 to l 1pl3 (24),
where the transcription factor tumor sup-
pressor gene WTI resides (60). For exam-
ple, Park et al. (61) reported a homozygous
mutation of this gene in a peritoneal
mesothelioma. Normal mesothelial tissue of
both humans and rats abundantly expresses
this gene (60-63). Amin et al. (62) found
that WTI mRNA was undetectable in 3 of
19 mesothelioma cell lines and in 3 of 8
mesothelioma tumors. In contrast, Walker
et al. (63) reported that the WTJ was ubiq-
uitously expressed by the human and rat
mesothelioma cell lines they studied,
although there was a relatively lower expres-
sion ofthe gene in the lines that gave rise to
sarcomatous tumors in nude mice. This
latter relationship could not be confirmed
byLangerak et al. (60). It is possible, how-
ever, that an aberration in WTI expression
could stabilize and sequester p53 protein
(64), thereby explaining the frequent
immunohistochemical detection of p53
in mesotheliomas.
Oncogenes in Mesotheliomas
Protooncogenes are genes that promote cell
division, and alterations in protooncogenes
may contribute to uncontrolled cell growth.
As noted above, nonrandom rearrangements
and polysomy ofchromosomes 1, 7, and 22
are also hallmarks ofhuman mesotheliomas.
These structural aberrations can generate
growth-promoting oncogenes by rearrange-
ments and amplification. Using Southern
blot analyses, Tiainen et al. (65) examined
23 mesotheliomas and found no rearrange-
ment and amplifications ofseveral onco-
genes located on these chromosomes, i.e.,
N-ras, epidermal growth factor receptor
(EGFR), Met, and PDGF-B chain. Further,
Kishimoto (66) could find no immunohis-
tochemical evidence ofoverexpression of
EGFR. On the other hand, Ramael et al.
(67) detected amplifications or rearrange-
ments ofEGFR in all three ofthe mesothe-
liomas they examined using a more sensitive
PCRassay. Thus, reevaluation ofthe known
oncogenes on chromosomes 1, 7, and 22
using PCR approaches may reveal addi-
tional loci that are frequently rearranged or
amplified in mesotheliomas.
Metcalfet al. (48) found no activating
mutations of the K-ras oncogene in the
20 mesothelioma cell lines they exam-
ined. Further, Lee et al. (68) reported that
overexpression ofras protein is a rare event
for mesotheliomas. More recently, how-
ever, Kishimoto (66) did find frequent
immunostaining of N-ras, and Ramael
et al. (69) found that more than 50% of
the cells within 78% ofthe mesotheliomas
they evaluated had immunoreactivity to
N-ras antibody. Notably, N-ras is located
on chromosome 1 which is often polysomic
in mesotheliomas. Finally, sustained
expressions ofc-jun and c-fos is induced by
fibers (70), and c-myc, along with c-neu
were found to be overexpressed in the
majority ofthe mesotheliomas ofJapanese
patients (66).
Many exogenous peptides increase the
growth rate of mesothelial cells (71-74),
and mesothelioma cells produce several
growth factors and cytokines (71,75-79).
Oncogenes often cause inappropriate
expression ofgrowth factors and/or their
receptors. As a consequence, normal growth
control mechanisms are abrogated.
Oncogenes causing the production of
growth factors that simulate autoreplica-
tion are referred to as autocrines (80).
Autocrine activity, shown not to be PDGF,
TGF-,, or EGF, has been detected in the
conditioned medium of a mesothelioma
cell line; however, the actual factor has not
been identified (81). Nonetheless, repeat-
edly observed alterations in the expression
of PDGF proteins and the associated
PDGF receptors by mesotheliomas have
suggested that this ligand and receptor pro-
duce an autocrine loop in many mesothe-
liomas (77,82). Several laboratories have
examined this possibility, with somewhat
conflicting and puzzling results.
PDGF-A-protein and PDGF-B-protein
chains dimerize to form three species of
PDGF that are each mitogenic for
mesothelioma cells. One is A-chain
homodimers and one is B-chain homod-
imers; the third is an A/B-chain het-
erodimer. The PDGF-A chain and
PDGF-B chains are coded by separate
genes, as are the two receptor proteins, a
and 3 (83). The A/B-chain heterodimer
and the B-chain homodimer are recog-
nized by the 3 receptor. All three forms of
PDGF bind the a receptor, although with
differing affinities. Therefore, alterations in
any of four different genes could affect
growth of mesothelial cells. Normal
mesothelial cells express the a and j recep-
tors (82-89). Mesotheliomas often over-
produce PDGF A-chain and B-chain
proteins and low levels, if any, of the ,B
receptor. Therefore, the PDGF-B-chain
protein produced by the mesotheliomas
may serve as an autocrine for continuous
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replication of the tumor cells (82,85,89).
However, mesothelioma cells also express
the PDGF-A-chain growth factor, and the
a receptor has been detected using RNase
protection assays and recently by run-off
analyses (83). In addition, transfection
experiments with the immortal but nontu-
morigenic human mesothelial cell MeT-5A
have shown that overexpression of the
PDGF-A chain will transform these cells to
the tumorigenic phenotype (90,91).
Further, it has been shown using antisense
oligonucleotides that the PDGF-A chain,
but not the PDGF-B chain, will inhibit the
growth ofmesothelioma cell lines but not
the MeT-5A cells (84). Thus, even though
the PDGF growth factors and their recep-
tors are differentially expressed in human
mesothelioma cells compared to their nor-
mal cell counterparts, the role of these
changes in the transformation ofmesothe-
lial cells is unclear. Parenthetically, rat
mesotheliomas do not produce any form of
PDGF, which suggests that fiber exposures
can produce dissimilar results in different
species (92,93).
The other growth factors and cytokines
that are produced by at least some human
mesothelioma cells include TGF-a,
TGF-,B1, TGF-P2, IGF-1, IL-la, IL-1p,
G-CSF, GM-CSF, M-CSF, IL-8, MCP-1,
LIF, TNF-a, IL-6, and IL-8 (71,75-78).
Both normal mesothelial cells and
mesotheliomas produce IGF-1 and
express the receptor for this growth factor
(94). Further, a hamster mesothelioma
cell line that was transfected with an
IGF-1 receptor antisense plasmid exhib-
ited both decreased growth in vitro and
tumorigenicity (95). These observations
suggest that IGF-1 may function as an
autocrine for both the normal and trans-
formed cells. Peritoneal mesothelial cells
secrete detectable amounts of IL-1 and
express the IL-1 receptor. However, an in
vivo role for IL-I as an autocrine for these
cells is unclear because exogenously added
IL-1 is required for long-term growth of
the cells in culture (79). IL-6 has been
shown to be an autocrine for normal
human mesothelial cells (76,80); it
remains to be determined if IL-6 is an
autocrine factor for mesotheliomas, as
well. IL-8, on the other hand, is only pro-
duced by mesothelioma cells (75); it is
not known whether the receptor for this
factor resides on the surface of mesothe-
lioma cells. However, because IL-8 is a
major angiogenesis factor (75), it may
play an important role in the growth of
the mesothelioma tumor.
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Figure 2. Possible steps in the genesis of a mesothelioma.
Conclusions
Although information is minimal on the
molecular changes that produce fiber-
associated malignant mesotheliomas, the
available data do show that point muta-
tions, partial deletions, inappropriate
expression, gene rearrangement and com-
plete gene loss, and possibly epigenetic
silencing and gene amplification probably
are all involved. Many ofthese aberrations
occur in the genes regulating the initiation
ofcell division, checking cell division rate,
maintaining the cytoskeleton, regulating
transcription, and inducing angiogenesis. It
is also known that these aberrations are
attributed to carcinogens other than
asbestos fibers. Thus, the molecular biology
underlying the genesis of these tumors is
not significantly different from other neo-
plasms attributed to nonfibrous carcino-
gens; only the actual battery of genetic
alterations seems to differ. The obser-
vations ofMeloni et al. (33) and Knuutila
et al. (24) along with the recent report
from Hansteen et al. (23) do, however,
permit a hypothesized ordering ofgenetic
changes in the genesis ofhuman mesothe-
lioma (Figure 2). Their models disagree,
but in general, they propose that losses of
chromosomes 6q, lp, and 22q may be
among the earliest events. Other areas of
data inconsistency include the specific
form of PDGF and PDGF receptor, the
status ofp53 and WTI, and the possible
role ofSV40 viral infection. Plausible rea-
sons for these discrepancies include inher-
ent species differences, dissimilar routes of
fiber exposure, and the creation of new
alterations that manifested themselves dur-
ing the development of cell lines. Some
discrepancies might be resolved by the
exchange oftumor specimens and cell lines
as well as protocols and reagents.
Mesothelioma invariably is diagnosed
late in the development of the disease
when treatment is no longer effective
(24). Therefore, a key to reducing the
mortality rate ofthis disease is knowledge
of the general sequence ofgenetic events
that transpire between initiation of
mesothelial cells and the emergence ofthe
metastatic tumor cells. As with all tumor
systems, but especially for mesothelioma,
considerable work remains to be done to
clarify which genetic changes are the most
important in transformation ofthe normal
cell. The ultimate resolution of these
changes will permit the designing of anti-
tumor treatment approaches that could
reverse the effects of the altered genes.
Future work will require confirmation of
the proposed model (Figure 2), clarifying
the role of the above discussed genetic
changes, and elucidating the importance
of as yet uninvestigated mechanisms, e.g.,
theinduction ofgenomic instability (96,97),
reduced DNA repair capacity (96), dis-
ruption ofprogrammed cell death (98),
and inherent susceptibility (99).
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